The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.
 
Douglas Adkins
Consulting or Advisory Role - Adlai Nortye; Boehringer Ingelheim; CUE Biopharma; Exelixis; Genmab/Seattle Genetics; Immunitas; InhibRx; Kura Oncology; Merck; Merck KGaA; Merus; NATCO Pharma; Purple Biotech; Regeneron; Sanofi; Seagen; TargImmune Therapeutics
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - NATCO Pharma (Inst)
 
Winston Wong
Research Funding - BioAtla; Hookipa Biotech
 
Jamal Misleh
No Relationships to Disclose
 
Jochen Lorch
Consulting or Advisory Role - Coherus BioSciences; Eisai
 
Jaspreet Grewal
Honoraria - Bristol-Myers Squibb/Roche; Curio Science
Consulting or Advisory Role - Castle Biosciences
Speakers' Bureau - Bristol-Myers Squibb/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; Castle Biosciences
 
Kathleen Kerrigan
Stock and Other Ownership Interests - bristol myers squibb (I)
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Genentech; Sanofi
Research Funding - AstraZeneca (Inst); BioAtla (Inst); Janssen (Inst); Merck (Inst); Merus NV (Inst)
 
Jeffery Russell
No Relationships to Disclose
 
Jeremy Cetnar
Employment - Oregon Health & Science University (OHSU) (I)
 
Alan Ho
Consulting or Advisory Role - AffyImmune Therapeutics; Coherus Biosciences; Eisai; Exelixis; Hookipa Biotech; InhibRx; Kura Oncology; Lepu Biopharma; Nested Therapeutics; Rgenta; Takeda
Speakers' Bureau - Mt. Sinai; Physicans' Education Resource
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Daiichi; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Hookipa Biotech; Kura Oncology; Merck; Novartis; OncC4; Poseida; Remix Therapeutics; Rgenta; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Kyechin Chen
Employment - BioAtla
Stock and Other Ownership Interests - BioAtla
Travel, Accommodations, Expenses - BioAtla
 
Judith Llorin-Sangalang
Employment - BioAtla
Stock and Other Ownership Interests - BioAtla
Travel, Accommodations, Expenses - BioAtla
 
Kartik Aysola
Employment - BioAtla
Stock and Other Ownership Interests - BioAtla
 
Jacob Thomas
Consulting or Advisory Role - Conjupro Biotherapeutics; Kura Oncology